AOBO board announces $20 million share buyback program American Oriental Bioengineering.

, , a pharmaceutical company focused on improving wellness through the development, produce and commercialization of a wide selection of prescription and over-the-counter items, announced at its 2010 earnings conference contact, held on March 15, 2011, that its board of directors certified a share buyback system for the repurchase as high as $20 million of the business’s outstanding common share over the next two years. Purchases under this scheduled plan may be made, every once in awhile, on view market, privately negotiated transactions, block trades, and accelerated stock usually repurchase transactions or, as determined by the business and will be funded from available working capital.Unwanted effects should become minimal. Because the adenovirus does not contain toxic components, the worst-case scenario will be that it could cause contamination in the body’s healthful cells, making flu-like symptoms that are treatable, Kim said. Investigators are testing the concept in mice and in the laboratory with individual pancreatic tumor cells. Pancreatic malignancy was selected due to its poor prognosis and current lack of effective therapies. Although it accounts for no more than two % of new cancer cases diagnosed yearly in the United States, it accounts for six % of cancer deaths.